EGFR and lung cancer: Another dual screen in EGFR-dependent PC9 lung cancer cells treated with erlotinib and the CDK7/12 inhibitor THZ1 showed that the suppression of multiple genes associated with transcriptional complexes enhanced the efficacy of the combination treatment [188].